Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
9.56
-0.92 (-8.78%)
At close: Dec 5, 2025, 4:00 PM EST
9.68
+0.12 (1.26%)
After-hours: Dec 5, 2025, 7:44 PM EST
Personalis Revenue
Personalis had revenue of $14.50M in the quarter ending September 30, 2025, a decrease of -43.62%. This brings the company's revenue in the last twelve months to $69.10M, down -21.02% year-over-year. In the year 2024, Personalis had annual revenue of $84.61M with 15.15% growth.
Revenue (ttm)
$69.10M
Revenue Growth
-21.02%
P/S Ratio
11.67
Revenue / Employee
$301,760
Employees
229
Market Cap
848.97M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PSNL News
- 17 days ago - Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 25 days ago - Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer - Business Wire
- 4 weeks ago - Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Personalis Reports Third Quarter 2025 Financial Results - Business Wire
- 6 weeks ago - Personalis to Announce Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing - Business Wire
- 2 months ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test - Business Wire